Back to search results

GLP-1R Agonist Therapy for Type 2 Diabetes in Spinal Cord Injury

This study is investigating whether semaglutide (also known as Ozempic), a medication used to control type 2 diabetes, is effective for people with spinal cord injury (SCI) who also have type 2 diabetes. People with SCI are at higher risk for this condition. You could be eligible if you are 18-70 years old, had a spinal cord injury more than one year ago, and have type 2 diabetes. The study will look at how semaglutide affects your blood sugar levels and other information related to type 2 diabetes and obesity. The study aims to see if semaglutide improves glucose tolerance (how your body handles sugar) and insulin action (how well your body uses insulin) over 24 weeks. The current status of this study is unclear.

Study design
This is an interventional study with 50 participants who will be randomly assigned to receive either semaglutide or a placebo (inactive saline solution) for 24 weeks.
What's involved
You would have 7-9 in-person visits and 9-10 phone visits over 24 weeks, including medical history reviews, blood tests, and specialized tests like a mixed meal tolerance test and a glucose clamp study.
Compensation
Not stated in the trial record.
Follow-up
After the 24-week treatment period, you will repeat the meal and glucose studies over two separate days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06706284

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

Recruiting
PHASE4Ages 18–70InterventionalTreatment
Marzieh Salehi
~50 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:Semaglutide Injectable ProductPlacebo

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Glucose tolerance
Measured over Baseline to 24 weeks
+1 more outcome measured

Conditions

Spinal Cord Injuries
Type 2 Diabetes

Explore related trials

Spinal Cord InjuryType 2 Diabetes Mellitus

Where it's being run

2 sites across 1 states
Texas2

Study leadership

  • Marzieh Salehi, MD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center at San Antonio

Who to contact

Marzieh Salehi, MD
[email protected]
210-567-6691
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Herbal preparations or drugs licensed for control of body weight or appetite (eg, orlistat, bupropion-naltrexone, phentermine-topiramate, phentermine, lorcaserin) within a year prior to the start of the study
Pioglitazone, SGLT2 or DPPIV inhibitors, GLP-1RA within the last 60 days at the time of screening 9. Severe allergy/hypersensitivity to any of the proposed study treatments, excipients, acetaminophen 10. Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus (T1DM) or diabetic ketoacidosis, or if the subject has been treated with daily SC insulin within 90 days prior to screening. 11. Significant inflammatory bowel disease or other severe disease or surgery affecting the upper GI tract (including weight-reducing surgery and procedures) which could affect the interpretation of safety and tolerability data. Prior history of bariatric surgery is not considered exclusion given the ample evidence of safety of use of GLP-1R therapy in this population. 12. Acute or chronic pancreatitis 13. Significant hepatic disease (except for metabolic dysfunction-associated steatohepatitis \[MASH\] or metabolic dysfunction-associated steatotic liver disease \[MASLD\]) without portal hypertension or cirrhosis) and/or subjects with any of the following results at screening:

What this trial measures

  • Glucose toleranceBaseline to 24 weeks

    The change in the incremental AUC Glucose3h response to meal ingestion

  • Insulin actionBaseline to 24 weeks

    Liver, adipose tissue and muscle insulin sensitivity determined using a two-step euglycemic clamp.